Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: The international telaprevir access program

Journal of Hepatology

Volumn 61, Issue 5, 2014, Pages 976-983

  Colombo, Massimo ^a   Strasser, Simone ^b   Moreno, Christophe ^c   Ferreira, Paulo Abrao ^d   Urbanek, Petr ^e   Fernández, Inmaculada ^f   Abdurakhmanov, Djamal ^g   Streinu Cercel, Adrian ^h   Verheyen, Anke ⁱ   Iraqi, Wafae ^j   DeMasi, Ralph ^k   Hill, Andrew ^l   Lonjon Domanec, Isabelle ^j   Wedemeyer, Heiner ^m  

^a UNIVERSITY OF MILAN   (Italy)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e CENTRAL MILITARY HOSPITAL   (Czech Republic)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^h CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

ⁱ JANSSEN RESEARCH FOUNDATION   (Belgium)

^j Janssen Pharmaceuticals   (France)

^k Tibotec Inc   (United States)

^l MetaVirology Ltd   (United Kingdom)

^m HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

Cirrhosis; Hepatitis C; Pegylated interferon; Telaprevir

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; OLIGOPEPTIDE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN; RIBAVIRIN;

ADULT; ANEMIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS VARICES BLEEDING; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATORENAL SYNDROME; HUMAN; HYPERBILIRUBINEMIA; INFECTION; INTENTION TO TREAT ANALYSIS; KIDNEY FAILURE; LIVER BIOPSY; LIVER CANCER; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; PRURITUS; RASH; RELAPSE; SUSTAINED VIROLOGICAL RESPONSE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIREMIA; AGED; CLASSIFICATION; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; VIROLOGY; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84932190976     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.06.005     Document Type: Article

References (39)

1. Mohd Hanafiah K, Groeger J, Flaxman A, Wiersma S. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57: 1333-1342.
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380: 2095-2128.
3. Davis G, Alter M, El-Serag H, Poynard T, Jennings L. Aging of Hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138: 513-521.
4. Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002;123: 483-491.
5. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, et al. Sustained virological response to interferon-Alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology 2007;45: 579-587.
6. van der Meer A, Veldt B, Feld J, Wedemeyer H, Dufour J, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308: 2584-2593.
7. Kwo P, Lawitz E, McCone J, Schiff E, Vierling J, Pound D, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alpha-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial. Lancet 2010;376: 705-716.
8. Poordad F, McCone J, Bacon B, Bruno S, Manns M, Sulkowski M, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364: 1195-1206.
9. Bacon B, Gordon S, Lawitz E, Marcellin P, Vierling J, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364: 1207-1217.
10. Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360: 1839-1850.
11. Jacobson I, McHutchison J, Dusheiko G, Di Besceglie A, Reddy K, Bzowej N, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364: 2405-2416.
12. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364: 2417-2428.
13. Pearlman B, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: A cure and so much more. CID 2011;52: 889-900.
14. Mallet V, Gilgenkrantz H, Serpaggi J, Verkarre V, Vallet-Pichard A, Fontaine H, et al. Brief communication: The relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008;149: 399-403.
15. D'Ambrosio R, Aghemo A, Rumi M, Ronchi G, Donato M, Paradis V, et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 2012;56: 532-543.
16. Cardoso A, Moucari R, Figueiredo-Mendes C, Ripault M, Giuily N, Castelnau C. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010;52: 652-657.
17. Kawamura Y, Ikeda K, Arase Y, Yatsuji H, Sezaki H, Hosaka T, et al. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 2007;120: 1034-1041.
18. Hsu Y, Lin J, Ho H, Kao Y, Huang Y, Hsiao N, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014;59: 1293-1302.
19. Arase Y, Kobayashi M, Suzuki F, Suzuki Y, Kawamura Y, Akuta N, et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology 2013;57: 964-973.
20. Backus L, Boothroyd D, Phillips B, Belperio P, Halloran J, Mole L. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011;9: 509-516.
21. Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC). J Hepatol 2013;59: 434-441.
22. Rutter K, Ferlitsch A, Maieron A, Stattermayer A, Graziadei I, Dulic M, et al. Safety of triple therapy with telaprevir or boceprevir in hepatitis c patients with advanced liver disease -Predictive factors for sepsis. J Hepatol 2013; 58: S30.
23. Hezode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014;147: 132-142.
24. Aronsohn A, Jensen D. Informed deferral: A moral requirement for entry into the hepatitis C virus treatment warehouse. Hepatology 2012;56: 1591-1592.
25. Colombo M, Fernandez I, Abdurakhmanov D, Ferreira P, Strasser S, Urbanek P, et al. Safety and on-Treatment efficacy of telaprevir: The early access programme for patients with advanced hepatitis C. Gut 2014;63: 1150-1158.
26. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128: 343-350.
27. Sherman K, Flamm S, Afdhal N, Nelson D, Sulkowski M, Everson G, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365: 1014-1021.
28. Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, et al. Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: A prospective clinical study. Ailment Pharmacol Ther 2013;38: 1076-1085.
29. European Association for Study of Liver. EASL clinical practice guidelines: Management of hepatitis C virus infection. J Hepatol 2014;60: 392-420.
30. McHutchison J, Lawitz E, Shiffman M, Muir A, Galler G, McCone J, et al. Peginterferon alpha-2b or alpha-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361: 580-593.
31. Marcellin P, Cheinquer H, Curescu M, Dusheiko G, Ferenci P, Horban A, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 2012;56: 2039-2050.
32. Vezali E, Aghemo A, Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther 2010;32: 2117-2138.
33. Shimada N, Tsubota A, Atsukawa M, Abe H, Ika M, Kato K. Alpha-fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype. J Med Virol 2014;86: 461-472.
34. Backus L, Belperio P, Shahoumian T, Cheung R, Mole L. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther 2014;39: 93-103.
35. De Meyer S, Dierynck I, Ghys A, Beumont M, Daems B, Van Baelen B. Characterisation of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the REALIZE trial. Hepatology 2012;56: 2106-2115.
36. Fattovich G, Ribero ML, Pantalena M, Diodati G, Almasio P, Nevens F, et al. Hepatitis C virus genotypes: Distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe. J Viral Hepat 2001;8: 206-216.
37. Forestier N, Zeuzem S. Triple therapy with telaprevir: Results in hepatitis C virus-genotype 1 infected relapsers and non-responders. Liver Int 2012;32: 44-50.
38. Everhart J, Lok A, Kim H, Morgan T, Lindsay K, Chung R, et al. Weight-related effects on disease progression in the hepatitis C antiviral long-Term treatment against cirrhosis trial. Gastroenterology 2009;137: 549-557.
39. Bressler B, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003;38: 639-644.